TLK286
information and resources from the National Cancer Institute
TLK286
A modified glutathione analog. TLK286 is selectively activated by glutathione S-Transferase P1-1 into an alkylating metabolite which forms covalent linkages with nucleophillic centers in tumor cell DNA, thereby inducing a cellular stress response and cytotoxicity, and decreasing tumor proliferation. S-transferase P1-1 is an enzyme that is overexpressed in many human malignancies.
|
|
|
|
news articles
Telik Announces Appointment of Michael K. Inouye as Senior Vice ... Mar 20, 2006
Yahoo! News (press release) The company's most advanced drug development candidate is TELCYTA (TLK286), a tumor-activated small molecule product candidate that is in Phase 3 registration ...
Telik's TELINTRA Demonstrates Positive, Clinically Significant ... Dec 11, 2005
Yahoo! News (press release) The company's most advanced drug development candidate is TELCYTA® (TLK286), a cancer cell-activated product candidate that is in three Phase 3 registration ...
Telik Announces Presentation at Lazard Capital Markets Life ... Nov 22, 2005
PR Newswire (press release), The company's most advanced drug development candidate is TELCYTA(TM) (TLK286), a tumor-activated small molecule product candidate. ...
|
|
